Retraction: Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: A randomized controlled trial (Mov Disord., (2006), 21, 7, (924-929), 10.1002/mds.20825);Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial

Movement Disorders

Volumn 21, Issue 7, 2006, Pages 924-929

  Sato, Yoshihiro ^a   Iwamoto, Jun ^b   Kanoko, Tomohiro ^c   Satoh, Kei ^c  

^a Mitate Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Alendronate; Hip fracture; Hypercalcemia; Parkinson's disease; Vitamin D

Indexed keywords

ALENDRONIC ACID; CALCIUM ION; DEOXYPYRIDINOLINE; ERGOCALCIFEROL; FOSAMAC; PLACEBO;

AGED; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG OVERDOSE; ESOPHAGITIS; FEMALE; FOLLOW UP; HIP FRACTURE; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; URINE LEVEL;

EID: 33746931673     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26699     Document Type: Erratum

References (23)

1. Aita JF. Why patients with Parkinson's disease fall. JAMA 1982; 247:515-516.
2. Chiu KY, Pun WK, Luk KDK, Chow SP. Sequential fractures of both hips in elderly patients: a prospective study. J Trauma 1992; 32:584-587.
3. Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for falls as a cause of hip fracture in women. N Engl J Med 1991;324:1326-1331.
4. Johnell O, Melton LJ, Atkinson EJ III, O'Fallon WM, Kurland LT. Fracture risk in patients with parkinsonism: a population-based study in Olmsted Country, Minnesota. Age Aging 1992;21:32-38.
5. Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH. Bone mineral density in patients with Parkinson's disease measured by dual photon absorptiometry. Nucl Med Commun 1994;15:173-177.
6. Taggart H, Crawford V. Reduced bone density of the hip in elderly patients with Parkinson's disease. Age Ageing 1995;24:326-328.
7. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997;49:1273-1278.
8. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001;82:89-93.
9. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1α-hydroxyvitamin D3 in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:64-68.
10. Sato Y, Honda Y, Kaji M, Asoh T, Hosowaka K, Kondo I, Satoh K. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 2002;31:114-118.
11. Sama AA, Khan SN, Myers ER, et al. High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. Clin Orthop 2004;425:135-142.
12. Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-Tung S, Rajatanavin R. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab 2003;21:421-427.
13. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003;5:65-74.
14. Rizzoli R, Greenspan SL, Bone G III, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-1996.
15. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
17. Komar L, Nieves J, Cosman F, Rubin A, Shen V, Lindsay R. Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc 1993;41:1057-1064.
18. Matsumoto C, Kushida K, Yamazaki K, Imose K, Inoue T. Metacarpal bone mass in normal and osteoporotic Japanese women using computed X-ray densitometry. Calcif Tissue Int 1994;55: 324-329.
19. Sato Y, Kanoko T, Yasuda H, Satoh K, Iwamoto J. Beneficial effect of etidronate therapy in immobilized hip fracture patients. Am J Phys Med Rehabil 2004;83:298-303.
20. Derisquebourg T, Dubois P, Devogelaer JP, et al. Automated computerized radiogrammetry of the second metacarpal and its correlation with absorptiometry of the forearm and spine. Calcif Tissue Int 1994;54:461-465.
21. Ramnemark A, Nyberg L, Borssén B, Olsson T, Gustafson Y. Fractures after stroke. Osteoporos Int 1998;8:92-95.
22. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006.
23. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.